Objective:The aim of this study was to investigate the protective effects of ginsenoside Rb1 and assess whether these protective effects are related to calcium/calmodulin-dependent protein kinaseⅡ(Ca MKⅡ).Methods:A myocardial ischemia(IS)rat.model and a myocardial H9 C2 cell hypoxia model were established.MI was induced by occluding the left anterior descending artery for 120 min.Ginsenoside Rb1(10 mg/kg)was administered 30 min before ischemia induction,and the treatment continued for 7 days.Results:In the rat IS injury model,ginsenoside Rb1 reduced myocardial infarct size,mean left ventricular diastolic pressure,incidence of arrhythmia,and levels of serum creatine kinase,lactate dehydrogenase,and malondialdehyde.However,the mean left ventricular systolic pressure,and maximal rising and falling rates of ventricular pressure(±dp/dtmax)increased.In the myocardial H9 C2 cell hypoxia model,ginsenoside Rb1 reduced intracellular calcium concentrations([Ca2+]i)during hypoxia,and markedly reversed the hypoxia-induced decrease in cell survival.Ginsenoside Rb1 was involved in the downregulation of CaMKⅡand the ryanodine receptor,as well as hypoxia-induced H9 C2 cell survival.Conclusion:The findings of the present study suggest that ginsenoside Rb1 attenuates MI injury in rats,partially through the downregulation of CaMKⅡexpression.
Wen-Jun ZhouJuan-Li LiQian-Mei ZhouFei-Fei CaiXiao-Le ChenYi-Yu LuMing ZhaoShi-Bing Su
Liver fibrosis is a primary cause of liver cirrhosis, and even hepatocarcinoma.Recently, the usage of mesenchymal stem cells(MSCs) has been investigated to improve liver fi brosis.It has been reported that the differentiation, proliferation and migration of MSCs can be regulated by traditional Chinese medicine treatment; however, the mechanisms are still unclear.In this article, the authors review the characteristics of MSCs such as multidirectional differentiation and homing, and its application in animal experiments and clinical trials.The authors also list areas that need further investigation, and look at the future prospects of clinical application of MSCs.
中药作为慢性胰腺炎(chron ic pancreatitis,CP)的治疗药物之一,对CP的临床症状和某些实验室指标都有改善作用,其有效性和特色优势已得到肯定。迄今的实验研究,已建立起各种CP实验动物模型。中药防治CP的实验从单体到单味中药再到中药复方都有涉及,一些研究已达到分子水平。概述中药防治CP的基础实验研究现状,为今后的研究提供参考。
[目的]研究和解利湿方对大鼠酒精性慢性胰腺炎(ACP)及胰腺基质金属蛋白酶-2(matrix metal prote-ase-2,MMP-2)及其组织抑制因子(tissue inhibitors of metal protease-1,TIMP)-1、TIMP-2蛋白表达的影响及相关机制。[方法]Lieber-DeCarli酒精流质饮食联合尾静脉注射脂多糖制备大鼠ACP模型。在不同浓度(2.170g/ml、1.085g/ml、0.543g/ml)的和解利湿方治疗4周后,采用苏木精-伊红和天狼猩红染色观察胰组织病理变化,West-ern blot法检测MMP-2、TIMP-1和TIMP-2蛋白的表达。[结果]与模型对照大鼠比较,高剂量的和解利湿方减少了大鼠酒精性慢性胰腺炎炎症及纤维化病变,并增加MMP-2蛋白的表达(P<0.05),减少TIMP-1(P<0.05)和TIMP-2(P<0.01)蛋白的表达,增加MMP-2和TIMP-1的比值(P<0.01)。[结论]高剂量的和解利湿方对ACP胰腺纤维化可能有一定的治疗作用,其机制可能与抗炎、调节胰腺组织MMP-2、TIMP-1和TIMP-2蛋白的表达有关。
